Researchers from Loyola Medicine and Loyola University Chicago conducted a 22-patient proof-of-concept study of response-guided therapy that reduced the time and cost of hepatitis C treatment. The data were presented at the annual meeting of the American Association for the Study of Liver Diseases.
Hurricane Maria struck Puerto Rico in September 2017 and crippled its health care system, and the CDC says it has not received samples to test for the mosquito-borne Zika virus from the island since. Puerto Rico health officials say no new cases of Zika infection have been detected, but a hospital-based testing program has found maternal rates of Zika virus infection remain as high as at the height of the epidemic in 2016.
A study found that hepatitis C viral remission rates were high among people who injected drugs even when their adherence to treatment with sofosbuvir/velpatasvir was imperfect. "Active and ongoing drug use should not be used as a justification to deny treatment to patients," Dr. Elana Rosenthal said at The Liver Meeting 2018.
Unum Therapeutics said it will report on data from an early-stage trial of its candidate ACTR707, in combination with Roche Holding's Rituxan, or rituximab, for patients with relapsed/refractory CD20-positive B-cell non-Hodgkin lymphoma at a meeting of the American Society of Hematology. Enrollment in the study is expected to be completed next year.
Dr. Joshua Bauml said liquid biopsies have the potential to be an alternative to tissue biopsies in assessing resistance to cancer treatments. "We draw blood and request urine samples from our patients all the time, and the ability to test this serially is very appealing when we consider the fact that resistance develops over time," Bauml said at the 36th Annual Chemotherapy Foundation Symposium.
Universal screening for hepatitis C virus infection is more cost-effective and efficient than risk-based screening in pregnant women, data show.
Laboratories adopting immunoassays for lipoprotein(a), which are designed to identify individuals at increased risk of cardiovascular disease, should determine providers' expectations on the targeted patient population and on guidelines for Lp(a) levels. Labs and clinicians should be aware of racial/ethnic differences in Lp(a) levels, particularly in African-Americans.
A Series A financing round has pulled in about $3.7 million for Canada-based medical technology firm Rna Diagnostics. Part of the proceeds will be used to commercialize the company's RNA disruption assay.
Chembio Diagnostic Systems' DPP Ebola Antigen System is the second rapid antigen fingerstick test granted emergency use authorization by the FDA to detect the Ebola virus in patients. It is the first that uses a mobile battery-operated reader, which allows it to provide diagnostic results outside of laboratories.
Almost 500,000 uninsured people in five states are expected to gain access to Medicaid coverage following the midterm elections, advocates say. Three states voted to expand Medicaid eligibility, while two others elected governors who have promised to support state legislation expanding their programs.
- Page 1